nach oben

European Journal of Clinical Microbiology & Infectious Diseases

Erschienen in:

25.08.2018 | Original Article

Molecular characterization of fluoroquinolones, macrolides, and imipenem resistance in Haemophilus influenzae: analysis of the mutations in QRDRs and assessment of the extent of the AcrAB-TolC-mediated resistance

verfasst von: Abdessalam Cherkaoui, Nadia Gaïa, Damien Baud, Stefano Leo, Adrien Fischer, Etienne Ruppe, Patrice François, Jacques Schrenzel

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

The aims of the present study were to characterize the mechanisms of resistance to fluoroquinolones, macrolides, and imipenem in Haemophilus influenzae, to assess the extent of the AcrAB-TolC-mediated resistance, and to define a core genome multilocus sequence typing (cgMLST) scheme for H. influenzae by using whole-genome sequencing. Four amino acid substitutions in GyrA (at Ser84 and Asp88), ParC (at Ser84), and ParE (at Asp420) were found to be closely associated to the MICs. We did not find any amino acid substitution surrounding the three highly conserved amino acid motifs in PBP3 related to imipenem resistance. All the isolates possessed the ermB gene. Carbonyl cyanide m-chlorophenylhydrazone (CCCP) decreased the MIC of imipenem by twofold for FQR-6 and fourfold for GE47 and GE88 strains. For erythromycin, the MICs were decreased by twofold. We found that the six FQR isolates were clustered in two groups. The number of different loci within FQR-1_FQR-3_FQR-5 cluster was 6, while FQR-2 and FQR-4 differed for 21 loci. FQR-1_FQR-3_FQR-5 and FQR-2_FQR-4 clusters were distant among each other and compared to 19 genomes downloaded from NCBI, to 8 strains heteroresistant to imipenem, and to 4 strains monoresistant to ciprofloxacin isolated in Denmark. We confirmed that specific amino acid substitutions in GyrA, ParC, and ParE are implicated in quinolone resistance. Additionally, the degree of resistance is related to the number of these amino acid substitutions. We provide robust evidence that drug efflux is one of the substantial mechanisms of imipenem and erythromycin resistance in H. influenzae.

Nur mit Berechtigung zugänglich

Rennie RP, Ibrahim KH (2005) Antimicrobial resistance in Haemophilus influenzae: how can we prevent the inevitable? Commentary on antimicrobial resistance in H. Influenzae based on data from the TARGETed surveillance program. Clin Infect Dis 41(Suppl 4):S234–S238CrossRef

Agrawal A, Murphy TF (2011) Haemophilus influenzae infections in the H. Influenzae type b conjugate vaccine era. J Clin Microbiol 49(11):3728–3732CrossRef

Erwin AL, Smith AL (2007) Nontypeable Haemophilus influenzae: understanding virulence and commensal behavior. Trends Microbiol 15(8):355–362CrossRef

Lode H, Allewelt M (2002) Role of newer fluoroquinolones in lower respiratory tract infections. J Antimicrob Chemother 50(1):151–154CrossRef

Ball P, Baquero F, Cars O, File T, Garau J, Klugman K, Low DE, Rubinstein E, Wise R, Consensus Group on R, Prescribing in Respiratory Tract I (2002) Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 49(1):31–40CrossRef

Cherkaoui A, Diene SM, Renzoni A, Emonet S, Renzi G, Francois P, Schrenzel J (2017) Imipenem heteroresistance in nontypeable Haemophilus influenzae is linked to a combination of altered PBP3, slow drug influx and direct efflux regulation. Clin Microbiol Infect 23(2):118 e119CrossRef

Du D, Wang Z, James NR, Voss JE, Klimont E, Ohene-Agyei T, Venter H, Chiu W, Luisi BF (2014) Structure of the AcrAB-TolC multidrug efflux pump. Nature 509(7501):512–515CrossRef

Tristram S, Jacobs MR, Appelbaum PC (2007) Antimicrobial resistance in Haemophilus influenzae. Clin Microbiol Rev 20(2):368–389CrossRef

Barriere SL, Hindler JA (1993) Ciprofloxacin-resistant Haemophilus influenzae infection in a patient with chronic lung disease. Ann Pharmacother 27(3):309–310CrossRef

10.

Bootsma HJ, Troelstra A, van Veen-Rutgers A, Mooi FR, de Neeling AJ, Overbeek BP (1997) Isolation and characterization of a ciprofloxacin-resistant isolate of Haemophilus influenzae from the Netherlands. J Antimicrob Chemother 39(2):292–293CrossRef

11.

Biedenbach DJ, Jones RN (2003) Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: prevalence results from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 46(1):55–61CrossRef

12.

Nazir J, Urban C, Mariano N, Burns J, Tommasulo B, Rosenberg C, Segal-Maurer S, Rahal JJ (2004) Quinolone-resistant Haemophilus influenzae in a long-term care facility: clinical and molecular epidemiology. Clin Infect Dis 38(11):1564–1569CrossRef

13.

Puig C, Tirado-Velez JM, Calatayud L, Tubau F, Garmendia J, Ardanuy C, Marti S, de la Campa AG, Linares J (2015) Molecular characterization of fluoroquinolone resistance in nontypeable Haemophilus influenzae clinical isolates. Antimicrob Agents Chemother 59(1):461–466CrossRef

14.

Georgiou M, Munoz R, Roman F, Canton R, Gomez-Lus R, Campos J, De La Campa AG (1996) Ciprofloxacin-resistant Haemophilus influenzae strains possess mutations in analogous positions of GyrA and ParC. Antimicrob Agents Chemother 40(7):1741–1744CrossRef

15.

Yokota S, Ohkoshi Y, Sato K, Fujii N (2008) Emergence of fluoroquinolone-resistant Haemophilus influenzae strains among elderly patients but not among children. J Clin Microbiol 46(1):361–365CrossRef

16.

Tsuji BT, Fisher J, Boadi-Yeboah R, Holden PN, Sethi S, Pettigrew MM, Murphy TF (2018) Azithromycin pharmacodynamics against persistent Haemophilus influenzae in chronic obstructive pulmonary disease. Antimicrob Agents Chemother 62(2)

17.

Atkinson CT, Kunde DA, Tristram SG (2017) Expression of acquired macrolide resistance genes in Haemophilus influenzae. J Antimicrob Chemother 72(12):3298–3301CrossRef

18.

EUCAST (2003) Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth dilution

19.

Fuursted K, Hartmeyer GN, Stegger M, Andersen PS, Justesen US (2016) Molecular characterisation of the clonal emergence of high-level ciprofloxacin-monoresistant Haemophilus influenzae in the region of southern Denmark. J Glob Antimicrob Resist 5:67–70CrossRef

20.

Cherkaoui A, Diene SM, Fischer A, Leo S, Francois P, Schrenzel J (2017) Transcriptional modulation of penicillin-binding protein 1b, outer membrane protein P2 and efflux pump (AcrAB-TolC) during heat stress is correlated to enhanced bactericidal action of imipenem on non-typeable Haemophilus influenzae. Front Microbiol 8:2676CrossRef

21.

Li X, Mariano N, Rahal JJ, Urban CM, Drlica K (2004) Quinolone-resistant Haemophilus influenzae in a long-term-care facility: nucleotide sequence characterization of alterations in the genes encoding DNA gyrase and DNA topoisomerase IV. Antimicrob Agents Chemother 48(9):3570–3572CrossRef

22.

Shoji H, Shirakura T, Fukuchi K, Takuma T, Hanaki H, Tanaka K, Niki Y (2014) A molecular analysis of quinolone-resistant Haemophilus influenzae: validation of the mutations in quinolone resistance-determining regions. J Infect Chemother 20(4):250–255CrossRef

23.

Cerquetti M, Giufre M, Cardines R, Mastrantonio P (2007) First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates. Antimicrob Agents Chemother 51(9):3155–3161CrossRef

24.

Ubukata K, Shibasaki Y, Yamamoto K, Chiba N, Hasegawa K, Takeuchi Y, Sunakawa K, Inoue M, Konno M (2001) Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob Agents Chemother 45(6):1693–1699CrossRef

25.

Osaki Y, Sanbongi Y, Ishikawa M, Kataoka H, Suzuki T, Maeda K, Ida T (2005) Genetic approach to study the relationship between penicillin-binding protein 3 mutations and Haemophilus influenzae beta-lactam resistance by using site-directed mutagenesis and gene recombinants. Antimicrob Agents Chemother 49(7):2834–2839CrossRef

26.

Kitaoka K, Kimura K, Kitanaka H, Banno H, Jin W, Wachino JI, Arakawa Y (2018) Carbapenem-non-susceptible Haemophilus influenzae with penicillin-binding protein 3 containing amino acid insertion. Antimicrob Agents Chemother

27.

Nakashima R, Sakurai K, Yamasaki S, Nishino K, Yamaguchi A (2011) Structures of the multidrug exporter AcrB reveal a proximal multisite drug-binding pocket. Nature 480(7378):565–569CrossRef

28.

Seyama S, Wajima T, Nakaminami H, Noguchi N (2017) Amino acid substitution in the major multidrug efflux transporter protein AcrB contributes to low susceptibility to azithromycin in Haemophilus influenzae. Antimicrob Agents Chemother 61(11)

29.

Hooper DC (1999) Mechanisms of fluoroquinolone resistance. Drug Resist Updat 2(1):38–55CrossRef

30.

Akasaka T, Onodera Y, Tanaka M, Sato K (1999) Cloning, expression, and enzymatic characterization of Pseudomonas aeruginosa topoisomerase IV. Antimicrob Agents Chemother 43(3):530–536CrossRef

31.

Takei M, Fukuda H, Kishii R, Hosaka M (2001) Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother 45(12):3544–3547CrossRef

32.

Fukuda H, Hori S, Hiramatsu K (1998) Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus. Antimicrob Agents Chemother 42(8):1917–1922CrossRef

33.

Perichon B, Tankovic J, Courvalin P (1997) Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 41(5):1166–1167CrossRef

34.

Takahashi H, Kikuchi T, Shoji S, Fujimura S, Lutfor AB, Tokue Y, Nukiwa T, Watanabe A (1998) Characterization of gyrA, gyrB, grlA and grlB mutations in fluoroquinolone-resistant clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 41(1):49–57CrossRef

35.

Dean CR, Narayan S, Daigle DM, Dzink-Fox JL, Puyang X, Bracken KR, Dean KE, Weidmann B, Yuan Z, Jain R, Ryder NS (2005) Role of the AcrAB-TolC efflux pump in determining susceptibility of Haemophilus influenzae to the novel peptide deformylase inhibitor LBM415. Antimicrob Agents Chemother 49(8):3129–3135CrossRef

36.

Park YK, Ko KS (2015) Effect of carbonyl cyanide 3-chlorophenylhydrazone (CCCP) on killing Acinetobacter baumannii by colistin. J Microbiol 53(1):53–59CrossRef

37.

Seyama S, Wajima T, Nakaminami H, Noguchi N (2016) Clarithromycin resistance mechanisms of epidemic beta-lactamase-nonproducing ampicillin-resistant Haemophilus influenzae strains in Japan. Antimicrob Agents Chemother 60(5):3207–3210CrossRef

Titel: Molecular characterization of fluoroquinolones, macrolides, and imipenem resistance in Haemophilus influenzae: analysis of the mutations in QRDRs and assessment of the extent of the AcrAB-TolC-mediated resistance
verfasst von: Abdessalam Cherkaoui
Nadia Gaïa
Damien Baud
Stefano Leo
Adrien Fischer
Etienne Ruppe
Patrice François
Jacques Schrenzel
Publikationsdatum: 25.08.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 11/2018
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-018-3362-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Molecular characterization of fluoroquinolones, macrolides, and imipenem resistance in Haemophilus influenzae: analysis of the mutations in QRDRs and assessment of the extent of the AcrAB-TolC-mediated resistance

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2018

Multicenter performance evaluation of the Unyvero IAI cartridge for detection of intra-abdominal infections

Current taxonomy of Rhodococcus species and their role in infections

A 5-year study of the performance of the Verigene Gram-positive blood culture panel in a pediatric hospital

An evaluation of risk factors to predict target concentration non-attainment in critically ill patients prior to empiric β-lactam therapy

Detection of Chlamydia trachomatis mRNA using digital PCR as a more accurate marker of viable organism

Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin